top of page
SS 31 50mg
SS 31 50mg

SS 31 50mg

$150.00Price
Quantity

SS-31 (ELAMIPRETIDE)

SS-31, also known as Elamipretide or Bendavia, is a small aromatic-cationic tetrapeptide that selectively targets mitochondria to protect and restore cellular energy production. Unlike traditional antioxidants that work broadly, SS-31 specifically binds to cardiolipin in the inner mitochondrial membrane, preventing lipid peroxidation and optimizing electron transport chain function. This unique mechanism makes it the first FDA-approved mitochondrial-targeting therapy, approved in 2025 for Barth syndrome, and is being researched for age-related decline, heart disease, and metabolic disorders.

MECHANISM OF ACTION

SS-31 works through direct mitochondrial targeting. The peptide's small size and cationic (positively charged) structure allow it to cross cell membranes and accumulate in mitochondria. Once inside, it binds to cardiolipin, a critical phospholipid in the inner mitochondrial membrane that anchors electron transport chain complexes.

By protecting cardiolipin from oxidative damage and lipid peroxidation, SS-31 optimizes electron transport chain efficiency, enhances ATP production, reduces reactive oxygen species (ROS) generation, and prevents mitochondrial dysfunction and apoptosis. This is fundamentally different from systemic antioxidants — it directly protects the machinery of cellular energy.

POTENTIAL BENEFITS

  • Dramatically improved cellular energy production and ATP levels

  • Reduced fatigue and enhanced exercise capacity

  • Faster recovery from physical exertion

  • Improved muscle strength and function

  • Enhanced cognitive clarity and mental stamina

  • Cardiac protection and improved heart function

  • Reduced oxidative stress at the mitochondrial level

  • Support for age-related mitochondrial decline

  • Neuroprotection and cognitive aging support

  • Improved metabolic flexibility and metabolic health

WHY IT'S BEING RESEARCHED

SS-31 is being researched because it represents a fundamentally new approach to treating mitochondrial dysfunction — the root cause of aging, heart disease, neurodegeneration, and metabolic disease.

Phase 2 trials in primary mitochondrial myopathy showed significant improvements in 6-minute walk test and fatigue scores with excellent safety. Its FDA approval in 2025 for Barth syndrome validates the mitochondrial-targeting approach and opens investigation into age-related mitochondrial decline, heart failure, and neurodegenerative conditions where mitochondrial dysfunction is central.

INTERESTING FACTS

  • First FDA-approved mitochondrial-targeting therapy — approved September 2025 under accelerated approval for Barth syndrome

  • Binds directly to cardiolipin, the signature phospholipid of the inner mitochondrial membrane

  • Small tetrapeptide (4 amino acids) — one of the smallest peptides in clinical use

  • Crosses cell membranes and accumulates in mitochondria without requiring active transport

  • Phase 2 trial showed significant improvements in muscle strength and fatigue in mitochondrial myopathy patients

  • No serious adverse events reported in clinical trials — excellent safety profile

  • Effects visible within days: subtle energy improvements by day 1–3, significant improvements by week 4–8

  • Can be used continuously without mandatory cycling

  • Targets the source of cellular energy production rather than acting as a general antioxidant

STACKING

Common research combinations include:

NAD+ for synergistic mitochondrial enhancement

SS-31 protects the inner mitochondrial membrane while NAD+ fuels the electron transport chain. Complementary mechanisms that work at different levels of mitochondrial function. No documented negative interactions.

MOTS-C for comprehensive metabolic and mitochondrial optimization

Both activate mitochondrial biogenesis and improve metabolic health. MOTS-C increases mitochondrial density while SS-31 optimizes function of existing mitochondria. Synergistic anti-aging effects.

SLU-PP-332 for exercise mimetic plus mitochondrial protection

SLU-PP-332 increases mitochondrial density via PGC-1α while SS-31 optimizes function of those new mitochondria. Complementary mechanisms with no known interactions.

Tirzepatide or Semaglutide for metabolic disease support

GLP-1 agonists improve insulin sensitivity and weight loss while SS-31 restores mitochondrial function underlying metabolic dysfunction. Early research suggests additive benefits with no documented interactions.

Semax or Selank for cognitive and neuroprotective synergy

SS-31 protects neuronal mitochondria while Semax/Selank enhance cognitive function through different pathways. Potential for combined neuroprotection and cognitive enhancement.

SS-31 is well-tolerated and has no documented serious interactions with other peptides or compounds in research settings.



RESEARCH PURPOSES ONLY

NOT AVAILABLE FOR HUMAN CONSUMPTION

    bottom of page